Nanoviricides (NNVC) Other Working Capital Changes (2011 - 2017)
Nanoviricides (NNVC) posted Other Working Capital Changes of -$14377.0 for Q1 2017, up 2.18% sequentially from -$14697.0 in Q4 2016, and down 337.75% YoY from $6047.0 in Q1 2016.
Nanoviricides (NNVC) Other Working Capital Changes (2011 - 2017) Analysis & Trends
Nanoviricides has reported Other Working Capital Changes for 5 years, with the latest figure at -$14377.0 in Q1 2017.
- Quarterly Other Working Capital Changes fell 337.75% year-over-year to -$14377.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was -$31705.0 (down 15.96% YoY) and the FY2015 annual result came in at -$150000.0, down 200.0% from the prior year.
- Other Working Capital Changes rose to -$14377.0 in Q1 2017 per NNVC's latest filing, from -$14697.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $150000.0 in Q2 2014 and troughed at -$150000.0 in Q3 2014.
- A 4-year average of -$8136.6 and a median of -$14158.0 in 2015 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2015 and 2017: Other Working Capital Changes soared 87.03% in 2015, then plunged 337.75% in 2017.
- Over 4 years, Other Working Capital Changes stood at -$150000.0 in 2014, then soared by 90.71% to -$13939.0 in 2015, then fell by 5.44% to -$14697.0 in 2016, then rose by 2.18% to -$14377.0 in 2017.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$14377.0, -$14697.0, and -$8678.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | Nanoviricides | 29.50 Mn | 26.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -14,377.00 |
| Mar 31, 2017 | -14,377.00 |
| Mar 31, 2017 | -14,377.00 |
| Dec 31, 2016 | -14,697.00 |
| Dec 31, 2016 | -14,697.00 |
| Dec 31, 2016 | -14,697.00 |
| Sep 30, 2016 | -8,678.00 |
| Sep 30, 2016 | -8,678.00 |
| Sep 30, 2016 | -8,678.00 |
| Mar 31, 2016 | 6,047.00 |
| Mar 31, 2016 | 6,047.00 |
| Mar 31, 2016 | 6,047.00 |
| Dec 31, 2015 | -13,939.00 |
| Dec 31, 2015 | -13,939.00 |
| Dec 31, 2015 | -13,939.00 |
| Sep 30, 2015 | -19,449.00 |
| Sep 30, 2015 | -19,449.00 |
| Sep 30, 2015 | -19,449.00 |
| Sep 30, 2014 | -150,000.00 |
| Sep 30, 2014 | -150,000.00 |